Ozmosi | Cediranib Drug Profile

Product Description

Cediranib is a potent small molecule vascular endothelial growth factor (VEGF) receptor tyrosine kinase (RTK) inhibitor of all three VEGF receptors (VEGFR-1, 2 and 3) at nanomolar concentrations. (Sourced from: https://nciformulary.cancer.gov/available_agents/Cediranib.htm)

Mechanisms of Action: VEGFR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: Europe
Company CEO: Pascal Soriot
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Cediranib

Countries in Clinic: Austria, Canada, France, Germany, Israel, Puerto Rico, South Korea, Spain, United States

Active Clinical Trial Count: 5

Recent & Upcoming Milestones

Highest Development Phases

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
NCT03851614	DAPPER	P2	Active, not recruiting	Colorectal Cancer\|Pancreatic Cancer\|Adenocarcinoma\|Leiomyosarcoma	2026-01-01	12%	2025-04-01	Primary Endpoints
NCT03660826	NCI-2017-01672	P2	Active, not recruiting	Adenocarcinoma\|Endometrioid Carcinoma\|Endometrial Cancer\|Carcinosarcoma	2024-12-06		2025-10-10	Patient Enrollment\|Primary Endpoints\|Treatments
NCT03334617	HUDSON	P2	Active, not recruiting	Non-Small-Cell Lung Cancer	2024-09-13	12%	2025-10-28
2019-001045-40	CEDUVEAL-M	P2	Active, not recruiting	Uveal Melanoma	2023-03-02		2022-03-13	Treatments
NCT04739800	NCI-2021-00615	P2	Active, not recruiting	Ovarian Cancer\|Transitional Cell Carcinoma\|Serous Cystadenocarcinoma\|Peritoneal Cancer\|Endometrioid Carcinoma\|Mucinous Cystadenocarcinoma\|Mucinous Adenocarcinoma\|Clear Cell Adenocarcinoma	2023-01-26		2024-11-27

Recent News Events

Date	Type	Title
05/09/2024	PubMed	Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial.
04/04/2024	PubMed	Feature Engineering-Assisted Drug Repurposing on Disease-Drug Transcriptome Profiles in Gastric Cancer.
02/21/2024	PubMed	Fibroblast Growth Factor Receptor Inhibitors Decrease Proliferation of Melanoma Cell Lines and Their Activity Is Modulated by Vitamin D.
10/28/2020	News Article	ENHERTU (fam-trastuzumab deruxtecan-nxki) Granted Priority Review in the US For the Treatment of HER2-positive Metastatic Gastric Cancer
10/12/2020	News Article	Immunomedics Announces FDA Orphan Drug Designation of Trodelvy™ for Adult and Pediatric Glioblastoma
09/18/2020	News Article	Immunomedics Announces Encouraging Early-Stage Clinical Results with Trodelvy™ in Brain Cancers
05/13/2020	News Article	AstraZeneca Advances the Science of Cancer Medicine With Practice-Changing Data at the ASCO20 Virtual Scientific Program

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Cediranib

Alternative Names: cediranib, recentin, azd2171 Clinical Status: Active Latest Update: 2025-10-27 Latest Update Note: Clinical Trial Update